Firategrast

an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system

Also Known As:

(1,1'-biphenyl)-4-propanoic acid, .alpha.-((2,6-difluorobenzoyl)amino)-4'(ethoxymethyl)-2',6'-dimethoxy-,(.alpha.S)-; (2S)-2-((2,6- difluorobenzoyl)amino)-3-(4'-(ethoxymethyl)-2',6'-dimethoxybiphenyl-4- yl)propanoic acid; SB-683699; SB683699

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Gold, M: 1 article (07/2013)
2.	Graff, O: 1 article (07/2013)
3.	Grove, R A: 1 article (07/2013)
4.	Havrdova, E: 1 article (07/2013)
5.	Horrigan, J: 1 article (07/2013)
6.	Pirruccello, S: 1 article (07/2013)
7.	Shackelford, S: 1 article (07/2013)
8.	Sopper, S: 1 article (07/2013)
9.	Atkinson, Gillian: 1 article (02/2012)
10.	Dua, Pinky: 1 article (02/2012)

Related Diseases

1.	Relapsing-Remitting Multiple Sclerosis 02/01/2012 - "Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial."
2.	Urinary Tract Infections (Urinary Tract Infection) 02/01/2012 - "The frequency of all adverse events was similar across all treatment groups except for an increased rate of urinary tract infections in the high-dose firategrast group. "
3.	Multiple Sclerosis 07/01/2013 - "Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis."
4.	Breast Neoplasms (Breast Cancer) 10/01/2023 - "Besides this, Firategrast could be introduced as a potential remedial agent for breast cancer patients. "